| Project/Area Number |
11671310
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Thoracic surgery
|
|---|
| Research Institution | Kanazawa University |
|---|
Principal Investigator |
ODA Makoto Kanazawa Univ., Dept. of Surgery, Assistant prof., 大学院・医学研究科, 講師 (50224241)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
OHTA Yasuhiko Kanazawa Univ., Dept. of Surgery, Assistant prof., 医学部・付属病院, 助手 (00272964)
渡辺 洋宇 金沢大学, 医学部, 教授 (20019897)
|
|---|
| Project Period (FY) |
1999 – 2000
|
| Project Status |
Completed (Fiscal Year 2001)
|
| Budget Amount *help |
¥1,400,000 (Direct Cost: ¥1,400,000)
Fiscal Year 2000: ¥500,000 (Direct Cost: ¥500,000)
Fiscal Year 1999: ¥900,000 (Direct Cost: ¥900,000)
|
|---|
| Keywords | Metastasis / Lung tumor / Lung perfusion / Chemotherapy |
|---|
| Research Abstract |
OBJECTIVE: This study was designed to evaluate the safety and the efficacy of isolated lung per fusion for the treatment of pulmonary metastases. METHODS: Acute study: Eighteen rabbits were randomized to undergo isolated left lung per fusion for 30 minutes with three different perfusates (n=6 per group): 37℃ linger solution, 37℃ water, and 42℃ linger solution. Chronic study: Cisptatin dosages of 0.8, 1.6, and 3.2mg/kg with 10ml linger solution were per fused via isolated lung perfusion in rats respectively (n=6 per group). The maximum tolerated dosage of cisptatin was determined by assessing the survival on day 14. RESULTS: In an acute study, there were no significant differences among the three groups in blood pressure, blood flow of the lung surface, and arterial oxygen pressure. In a chronic model, all animals treated with cisptatin dosages of 0.8 and 1.6mg/kg survived 14 days. Three animals treated with cisptatin dosages of 3.2mg/kg died within 14 days, and 3 animals treated with cisptatin dosages of 3.2mg/kg survived 14 days. CONCLUSIONS: This study demonstrated the safety and the efficacy of isolated lung perfusion. Phase I and II study for the patients with pulmonary metastases with isolated lung perfusion will be expected.
|
